Lupin Pithampur plant Completes Successful UK MHRA Inspection
Mumbai: Lupin Limited has announced the successful close out of the inspection carried out by the Medicines and Healthcare products Regulatory Agency (MHRA), the regulatory agency of the United Kingdom (UK), at its three manufacturing units in Pithampur (India).
The inspection for the three units at Pithampur (Unit I, Unit II, and Unit III) was conducted in January 2020.
Commenting on the positive outcome, Nilesh Gupta, Managing Director, Lupin said, "We are committed to maintaining truly global quality standards at all our manufacturing facilities. The successful close out of the inspection at Pithampur and release of the inspection report by UK MHRA further bolsters our confidence in our quality standards and manufacturing processes."
Lupin Limited is a global pharmaceutical company based in Mumbai, Maharashtra, India.
The Company develops and commercializes a wide range of branded and generic formulations, biotechnology products and APIs in over 100 markets in the U.S., India, South Africa, and across the Asia Pacific (APAC), Latin America (LATAM), Europe and Middle-East regions.
The Company specializes in the cardiovascular, anti-diabetic, and respiratory segments and has a significant presence in the anti-infective, gastro-intestinal (GI), central nervous system (CNS), and women's health areas.
The Company invests 9.6 % of its revenues on research and development.
Read also: Lupin Launches Jan Kovid Helpline in Mumbai
